IS6286A - Efnasambönd til meðhöndlunar á blóðþurrð - Google Patents

Efnasambönd til meðhöndlunar á blóðþurrð

Info

Publication number
IS6286A
IS6286A IS6286A IS6286A IS6286A IS 6286 A IS6286 A IS 6286A IS 6286 A IS6286 A IS 6286A IS 6286 A IS6286 A IS 6286A IS 6286 A IS6286 A IS 6286A
Authority
IS
Iceland
Prior art keywords
treatment compounds
ischemic treatment
ischemic
compounds
treatment
Prior art date
Application number
IS6286A
Other languages
English (en)
Inventor
Masamune Hiroko
Paul Deninno Michael
William Scott Robert
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6286A publication Critical patent/IS6286A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
IS6286A 1999-09-30 2002-02-26 Efnasambönd til meðhöndlunar á blóðþurrð IS6286A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30
PCT/IB2000/001353 WO2001023399A1 (en) 1999-09-30 2000-09-22 Compounds for the treatment of ischemia

Publications (1)

Publication Number Publication Date
IS6286A true IS6286A (is) 2002-02-26

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6286A IS6286A (is) 1999-09-30 2002-02-26 Efnasambönd til meðhöndlunar á blóðþurrð

Country Status (41)

Country Link
EP (1) EP1216257B1 (is)
JP (1) JP2003510331A (is)
KR (1) KR100481605B1 (is)
CN (1) CN1374967A (is)
AP (1) AP2002002458A0 (is)
AR (1) AR029887A1 (is)
AT (1) ATE312117T1 (is)
AU (1) AU778185B2 (is)
BG (1) BG106636A (is)
BR (1) BR0014384A (is)
CA (1) CA2386079A1 (is)
CO (1) CO5180581A1 (is)
CR (1) CR6592A (is)
CZ (1) CZ20021020A3 (is)
DE (1) DE60024649D1 (is)
EA (1) EA005422B1 (is)
EC (1) ECSP003682A (is)
EE (1) EE200200172A (is)
GE (1) GEP20043241B (is)
GT (1) GT200000161A (is)
HK (1) HK1049011A1 (is)
HR (1) HRP20020253A2 (is)
HU (1) HUP0202807A3 (is)
IL (1) IL148222A0 (is)
IS (1) IS6286A (is)
MA (1) MA26822A1 (is)
MX (1) MXPA02003308A (is)
MY (1) MY133996A (is)
NO (1) NO20021474L (is)
NZ (1) NZ517177A (is)
OA (1) OA12021A (is)
PA (1) PA8503301A1 (is)
PE (1) PE20010696A1 (is)
PL (1) PL357371A1 (is)
SK (1) SK4182002A3 (is)
TN (1) TNSN00191A1 (is)
TR (1) TR200200843T2 (is)
UA (1) UA73525C2 (is)
WO (1) WO2001023399A1 (is)
YU (1) YU23102A (is)
ZA (1) ZA200202461B (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
JP2005511590A (ja) * 2001-11-02 2005-04-28 アベンティス・ファーマスーティカルズ・インコーポレイテツド アデノシンａ１／ａ２アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
CN101385738A (zh) 2002-04-18 2009-03-18 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
EP1687268A1 (en) * 2003-11-10 2006-08-09 Schering Aktiengesellschaft Benzylether amine compounds useful as ccr-5 antagonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP2008504228A (ja) 2004-03-24 2008-02-14 ファスジェン・リミテッド・ライアビリティ・カンパニー Ａｍｐ活性化プロテインキナーゼの薬理学的阻害による新規神経保護方法
CN101001836B (zh) 2004-05-07 2010-12-22 詹森药业有限公司 作为11-β羟基类固醇脱氢酶抑制剂的吡咯烷-2-酮和哌啶-2-酮衍生物
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DK1778239T3 (da) * 2004-07-28 2013-12-02 Can Fite Biopharma Ltd Adenosin-a3-receptor-agonister til behandling af sygdomme forbundet medtørre øjne, herunder sjögrens syndrom
US20080221203A1 (en) * 2004-08-09 2008-09-11 University Catholique De Louvain Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease
US8563591B2 (en) 2004-08-30 2013-10-22 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
DE602005018509D1 (de) * 2004-08-30 2010-02-04 Janssen Pharmaceutica Nv N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
NZ567124A (en) 2005-10-21 2011-08-26 Novartis Ag Human antibodies against Interleukin-13 and therapeutic uses to treat asthma
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
CN101910153B (zh) 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
BR112014027983B1 (pt) 2012-05-08 2022-05-24 Aeromics, Inc Uso de inibidores de aquaporina seletivos
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
ES2834131T3 (es) * 2013-11-06 2021-06-16 Aeromics Inc Nuevas sales de profármacos
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (is) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists

Also Published As

Publication number Publication date
PA8503301A1 (es) 2003-06-30
GT200000161A (es) 2002-03-22
AU7035200A (en) 2001-04-30
EA200200316A1 (ru) 2002-08-29
PE20010696A1 (es) 2001-07-05
JP2003510331A (ja) 2003-03-18
TNSN00191A1 (fr) 2005-11-10
WO2001023399A1 (en) 2001-04-05
BR0014384A (pt) 2002-07-02
TR200200843T2 (tr) 2002-07-22
EE200200172A (et) 2003-06-16
MA26822A1 (fr) 2004-12-20
KR100481605B1 (ko) 2005-04-08
EP1216257B1 (en) 2005-12-07
ATE312117T1 (de) 2005-12-15
ZA200202461B (en) 2003-05-28
BG106636A (bg) 2003-01-31
IL148222A0 (en) 2002-09-12
MY133996A (en) 2007-11-30
EA005422B1 (ru) 2005-02-24
HUP0202807A2 (hu) 2002-12-28
KR20020034206A (ko) 2002-05-08
AP2002002458A0 (en) 2002-06-30
GEP20043241B (en) 2004-05-25
CO5180581A1 (es) 2002-07-30
CR6592A (es) 2004-02-23
NO20021474D0 (no) 2002-03-25
OA12021A (en) 2006-04-19
YU23102A (sh) 2006-01-16
SK4182002A3 (en) 2003-04-01
PL357371A1 (en) 2004-07-26
DE60024649D1 (de) 2006-01-12
UA73525C2 (en) 2005-08-15
NZ517177A (en) 2003-10-31
AU778185B2 (en) 2004-11-18
CZ20021020A3 (cs) 2003-04-16
HK1049011A1 (zh) 2003-04-25
AR029887A1 (es) 2003-07-23
HUP0202807A3 (en) 2005-02-28
MXPA02003308A (es) 2002-10-04
NO20021474L (no) 2002-05-22
CA2386079A1 (en) 2001-04-05
EP1216257A1 (en) 2002-06-26
CN1374967A (zh) 2002-10-16
HRP20020253A2 (en) 2004-04-30
ECSP003682A (es) 2002-04-23

Similar Documents

Publication Publication Date Title
IS6286A (is) Efnasambönd til meðhöndlunar á blóðþurrð
EE200100502A (et) Ühendid
NO20021637L (no) Kjemikalske forbindelser
PT1202994E (pt) Novos compostos
EE200200224A (et) Uudsed ühendid
IS5982A (is) Aðferð til framleiðslu á 5-sýanóþalíði
IS2711B3 (is) Aðferð til framleiðslu á amín platínu komplexum
IS6139A (is) Ný efnasambönd
ID29533A (id) Senyawa-senyawa kalsilitik
ID30127A (id) Komposisi-komposisi pelepasan terkontrol betahistin
NO20020466L (no) Kalsilytiske forbindelser
IS6141A (is) Ný efnasambönd
NO20014262D0 (no) Tiazoloindolinon-forbindelser
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
ATA203199A (de) Ablauf
FI991460A0 (fi) Parannettu Ca-N-P-liuoslannoite
DE29902506U1 (de) Mauerstein
IT1309173B1 (it) Apparecchio pigliafiocco.
SE9901117D0 (sv) Novel compounds
SE9903838D0 (sv) Novel compounds
SE9902764D0 (sv) Novel compounds
SE9903080D0 (sv) Novel compounds
SE9904651D0 (sv) Novel compounds
SE9901078D0 (sv) Novel compounds
SE9901271D0 (sv) Novel compounds